Lee's Pharmaceutical Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	9.7yrs
Board average tenure	11.1yrs

Recent management updates

Recent updates

CEO

Lee's Pharmaceutical Holdings has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Siu Fong Lee	Chairman & Compliance Officer	no data	HK$12.18m	0.14% HK$ 117.1k
Xiaoyi Li	Founder	3.2yrs	HK$6.54m	9.99% HK$ 8.6m
Wanee Leelalertsuphakun	MD, Chief Marketing & Sales Officer and Executive Director	20.8yrs	HK$13.20m	1.34% HK$ 1.1m
Yiu Ming Chow	Group CFO & Company Secretary	9.7yrs	no data	no data
Yueshen Chen	Director of Administration in China	no data	no data	no data
Tsui Victor Kailok	Group Chief Manufacturing Officer	12.4yrs	no data	no data
Yuanjue Sun	Chief Medical Officer	2.8yrs	no data	no data
Zhongyu Jiao	Group Deputy GM & GM of the Risk Control Centre	no data	no data	no data

9.7yrs

Average Tenure

61yo

Average Age

Experienced Management: L1PA's management team is seasoned and experienced (9.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Siu Fong Lee	Chairman & Compliance Officer	no data	HK$12.18m	0.14% HK$ 117.1k
Xiaoyi Li	Founder	no data	HK$6.54m	9.99% HK$ 8.6m
Wanee Leelalertsuphakun	MD, Chief Marketing & Sales Officer and Executive Director	no data	HK$13.20m	1.34% HK$ 1.1m
James Gale	Non-Executive Director	2.4yrs	HK$300.00k	no data
Yau Ching Chan	Independent Non-Executive Director	22.4yrs	HK$216.00k	0.088% HK$ 76.0k
Wah Keung Tsim	Independent Non-Executive Director	19.8yrs	HK$216.00k	0.051% HK$ 43.9k
Yee Wah Cheang	Independent Non Executive Director	1.1yrs	HK$135.00k	no data

11.1yrs

Average Tenure

65yo

Average Age

Experienced Board: L1PA's board of directors are seasoned and experienced ( 11.1 years average tenure).

Lee's Pharmaceutical Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Less than half of directors are independent

Board Member recently bought €55k worth of stock

Board Member recently bought €55k worth of stock

Recent updates

Upcoming dividend of HK$0.01 per share

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Market cap size

New major risk - Share price stability

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought €55k worth of stock

Board Member recently bought €55k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age